Sumitomo Mitsui Trust Group
SYRS

Sumitomo Mitsui Trust Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-516,629
Closed -$38.6M – 1217
2021
Q1 		$38.6M Buy
516,629
+78,430
+18% +$8.15M 0.02% 608
2020
Q4 		$47.5M Buy
438,199
+19,964
+5% +$1.82M 0.03% 553
2020
Q3 		$37M Sell
418,235
-54,242
-11% -$6.16M 0.02% 574
2020
Q2 		$50.4M Sell
472,477
-20,044
-4% -$1.8M 0.04% 494
2020
Q1 		$29.2M Sell
492,521
-4,945
-1% -$335K 0.03% 568
2019
Q4 		$34.4M Buy
497,466
+34,089
+7% +$2.07M 0.03% 585
2019
Q3 		$48.1M Buy
463,377
+304,472
+192% +$28.8M 0.04% 459
2019
Q2 		$14.7M Buy
158,905
+90,457
+132% +$6.3M 0.01% 697
2019
Q1 		$6.26M Buy
+68,448
New +$4.77M 0.01% 708

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $101M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return